Supplementary Files
Keywords
Diabetes mellitus
COVID-19
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To review the specialized literature on how adequate management of glycemic control can influence better outcomes in diabetic patients with Covid-19 who are receiving treatment with dexamethasone. Bibliographic review: Dexamethasone demonstrated a reduction in Covid-19 mortality, with widespread use in medical practice in the period reviewed. However, as it is a glucocorticoid, its use induces significant hyperglycemia, especially in patients who have previously had diabetes or are predisposed to developing it. Hyperglycemic states have been associated with worse outcomes in disease caused by Sars-cov-2. Effective glycemic control is required in the management of patients with hyperglycemia and the use of corticosteroids in diabetic patients should be carefully indicated. Final considerations: Dexamethasone has shown benefits in patients with Covid-19 using oxygen therapy, however its use in diabetic patients can cause significant hyperglycemia. Better glycemic control in patients with Covid-19 is associated with better outcomes and lower mortality, and should always be considered indispensable by the care team.
References
ALESSI J, et al. Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. Diabetol Metab Syndr, 2020; 7(12): 80.
ASIRI AA, et al. Assessment of the Effectiveness of a Protocol to Manage Dexamethasone-Induced Hyperglycemia Among Hospitalized Patients With COVID-19. Endocr Pract, 2021; 27(12): 1232-1241.
CARDOZA-JIMÉNEZ KJ, et al. Daily glucose variation influenced by the use of corticosteroids in COVID-19 patients treated in Lima-Peru. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2021; 15: 102188.
CHEN F, et al. Potential Adverse Effects of Dexamethasone Therapy on COVID-19 Patients: Review and Recommendations. Infect Dis Ther, 2021.
GARCÍA-ULLOA AC, et al. Recommendations for Glycemic Treatment for Patients Receiving Dexamethasone for Treatment of COVID-19. International Journal of Diabetes and Endocrinology, 2021; IJDE-111.
HORBY P, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med., 2021; 384(8): 693-704.
LIMA BC, et al. Fisioterapia pulmonar: Reabilitação pulmonar e muscular pós COVID-19. Brazilian Journal of Development, 2021; 7(11): 107710- 107722.
RAFIULLAH M, SIDDIQUI K. Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019. J Comp Eff Res, 2020;9(18):1247-1254.
RAYMAN G, et al. Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes. Diabet Med., 2021; 38(1): e14378.
RED ARGENTINA PÚBLICA DE EVALUACIÓN DE TECNOLOGÍAS SANITARIAS (REDARETS). Uso de dexametasona en pacientes internados con COVID-19. 2020. Disponível em: https://pesquisa.bvsalud.org/portal/resource/pt/biblio-1116529. Acessado em: 10 de janeiro de 2022.
SHIMIZU N, et al. Clinical feasibility of remote intermittently scanned continuous glucose monitoring in coronavirus disease 2019 patients with and without diabetes during dexamethasone therapy. Endocrine Journal Advance Publication, 2021;EJ21-0540.
SINGH AK, et al. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective. Diabetes Metab Syndr, 2020;14(5):971-978.
TOMAZINI BM, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA, 2020; 324(13): 1307-1316.
WORLD HEALTH ORGANIZATION (WHO). World Health Organization rapid evidence appraisal for Covid-19 therapies (WHO REACT). Rapid Evidence Appraisal for COVID-19 Therapies (REACT). Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA, 2020; 324(13): 1330-1341.
YOUNES YR, et al. COVID-19 and dexamethasone-induced hyperglycaemia: Workload implications for diabetes inpatient teams. Diabet Med., 2021; 39(2): e14716.